Literature DB >> 22609295

Progressive familial intrahepatic cholestasis and inborn errors of bile acid synthesis.

Irena Jankowska1, Piotr Socha.   

Abstract

Progressive familial intrahepatic cholestasis (PFIC), types 1, 2 and 3, are due to defects in genes involved in bile secretion (FIC1, BSEP, MDR3). PFIC and inborn errors of bile acid synthesis (IEBAS) often present in infancy with cholestasis. The distinctive feature of PFIC 1 and 2 and IEBAS is a normal level of GGT, while IEBAS are suspected in patients with low plasma bile acids concentration. Molecular testing, urinary bile acid analysis (IEBAS), liver biopsy and immuno-staining are used for the diagnosis. Some patients with PFIC can be successfully treated with ursodeoxycholic acid or partial external biliary diversion. IEBAS is treated with cholic acid. Liver transplantation is required for cirrhosis with liver failure. Hepatocarcinoma has been reported in PFIC2.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609295     DOI: 10.1016/j.clinre.2012.03.020

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  3 in total

Review 1.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

2.  Reverse of Acute and Chronic Morphine Tolerance by Lithocholic Acid via Down-Regulating UGT2B7.

Authors:  Zizhao Yang; Li Li; Haihong Hu; Mingcheng Xu; Jingkai Gu; Zaijie Jim Wang; Lushan Yu; Su Zeng
Journal:  Front Pharmacol       Date:  2016-11-01       Impact factor: 5.810

3.  Diagnosis of ABCB11 gene mutations in children with intrahepatic cholestasis using high resolution melting analysis and direct sequencing.

Authors:  Guorui Hu; Ping He; Zhifeng Liu; Qian Chen; Bixia Zheng; Qihua Zhang
Journal:  Mol Med Rep       Date:  2014-06-20       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.